Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome ...

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...

We recently published a list of UBS’ Top Quant Stocks In AI, IT, Healthcare & Other Sectors: Top 33 Stocks In All Sectors. In ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.

An American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan. This top ...

The stock’s volatility is typical for clinical-stage biotech companies, which can experience significant price swings based on trial results, regulatory updates, and market sentiment. Moreover, the ...

Covered bonds are listed on the Dublin Stock Exchange. The October net loss of LHV Bank ... as well as loans to small and medium-sized enterprises. Sie sollten jetzt in Biotech-Aktien einsteigen, weil ...